Cliff Asness’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.14M Buy
+931,658
New +$3.81M ﹤0.01% 2990
2024
Q4
– Sell
-815
Closed -$10.1K – 2909
2024
Q3
$10.1K Sell
815
-49,053
-98% -$610K ﹤0.01% 2748
2024
Q2
$649K Buy
49,868
+41,480
+495% +$687K ﹤0.01% 1934
2024
Q1
$190K Sell
8,388
-31,488
-79% -$552K ﹤0.01% 2259
2023
Q4
$517K Buy
39,876
+6,423
+19% +$86.5K ﹤0.01% 1868
2023
Q3
$672K Buy
33,453
+22,517
+206% +$505K ﹤0.01% 1747
2023
Q2
$294K Buy
10,936
+5,568
+104% +$240K ﹤0.01% 1949
2023
Q1
$313K Buy
5,368
+1,258
+31% +$62.1K ﹤0.01% 1932
2022
Q4
$210K Sell
4,110
-3,402
-45% -$236K ﹤0.01% 2070
2022
Q3
$615K Buy
7,512
+6,004
+398% +$448K ﹤0.01% 1700
2022
Q2
$102K Sell
1,508
-347
-19% -$31.8K ﹤0.01% 2086
2022
Q1
$205K Buy
+1,855
New +$231K ﹤0.01% 2056
2020
Q4
– Sell
-5,851
Closed -$1.28M – 2227
2020
Q3
$1.28M Sell
5,851
-224
-4% -$54.8K ﹤0.01% 1294
2020
Q2
$1.73M Buy
6,075
+2,094
+53% +$619K ﹤0.01% 1223
2020
Q1
$1.15M Buy
3,981
+3,208
+415% +$885K ﹤0.01% 1286
2019
Q4
$222K Buy
+773
New +$168K ﹤0.01% 1984
2019
Q1
– Sell
-1,706
Closed -$240K – 2194
2018
Q4
$240K Sell
1,706
-345
-17% -$58.2K ﹤0.01% 2034
2018
Q3
$524K Buy
2,051
+774
+61% +$214K ﹤0.01% 1944
2018
Q2
$325K Buy
+1,277
New +$316K ﹤0.01% 2105
2015
Q2
– Sell
-947
Closed -$435K – 2236
2015
Q1
$435K Buy
947
+140
+17% +$60.4K ﹤0.01% 1743
2014
Q4
$453K Buy
+807
New +$458K ﹤0.01% 2013

Other funds holding KPTI

Cliff Asness's KPTI Position: Q3 2026 in Review

Cliff Asness opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 931,658 shares worth $1.14M. The stake represents ﹤0.01% of the portfolio and ranks #2990 among its holdings. This is a return to the name: Cliff Asness previously reported a position in KPTI as recently as Q3 2024.

Cliff Asness first reported a position in KPTI in Q4 2014 and has held it in 21 quarters since. The position peaked at $1.73M in Q2 2020. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Cliff Asness held 931,658 shares of Karyopharm Therapeutics worth $1.14M as of Q3 2026.
  • Karyopharm Therapeutics was a new Cliff Asness position in Q3 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q3 2026, its #2990 holding.
  • Cliff Asness first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 21 quarters since.
  • Cliff Asness's Karyopharm Therapeutics position peaked at $1.73M in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.